© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
European Committee for Treatment and Research in Multiple Sclerosis
Benjamin M. Segal, MD: Escalation Versus Induction in MS
November 27, 2020
The chair of the department of neurology at The Ohio State University spoke to the ongoing conversation in MS about how aggressive to be with treatment early on.
Benjamin M. Segal, MD: The Multiple Sclerosis Prodrome
November 20, 2020
The chair of the department of neurology at The Ohio State University discussed the idea of the multiple sclerosis prodrome, presented in a plenary address at the MS Virtual 2020 meeting.
Benjamin M. Segal, MD: MS Virtual 2020 Highlights
November 19, 2020
The chair of the department of neurology at The Ohio State University discussed some of the main themes and takeaways from the MS Virtual 2020 meeting.
Satralizumab Benefits Relapse Risk Across NMOSD Treatment Spectrum
September 29, 2020
The medical director manager of neuroscience at Genentech offered her perspective on the mountain of data presented at MS Virtual 2020 on the recently approved NMOSD treatment.
Ponesimod Shows Safe Cardiac Profile in MS
September 28, 2020
Researchers concluded that uptitration of ponesimod was not associated with clinically significant bradyarrhythmia events; none were serious or lead to discontinuation.
Stephen L. Hauser, MD: Fenebrutinib and BTK Inhibition in Progressive MS
September 26, 2020
The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.
Low-Dose Rituximab Safe, as Effective as High Dose in MS
September 24, 2020
In the third year of treatment, both dose cohorts did not experience any contrast-enhancing lesions, and only a small population in the Barcelona center showed new T2 lesions.
Ocrelizumab Shows Range of Benefits for Spectrum of Patients With Multiple Sclerosis
September 24, 2020
The medical director manager of neuroscience at Genentech discussed the swath of data presented on the humanized anti-CD20 monoclonal antibody at MS Virtual.
Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach
September 23, 2020
Early intensive treatment was more effective in controlling disability progression over time compared with an escalation therapy approach.
Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS
September 23, 2020
The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.